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Anders Lindahl a, Johan Hyllner b, Raimund Strehl ba Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska University Hospital,
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Göteborg University, Medicinaregatan 11, Box 432, SE-405 30 Gothenburg, SwedenReceived 24 October 2008; received in revised form 20 April 2009; accepted 7 May 2009Abstract Tissue engineering and cell therapy require large-scale production of homogeneous populations of
lineage-restricted progenitor cells that easily can be induced to differentiate into a specific tissue. We have developed
straightforward protocols for the establishment of human embryonic stem (hES) cell-derived mesenchymal progenitor
(hES-MP) cell lines. The reproducibility was proven by derivation of multiple hES-MP cell lines from 10 different hES cell
lines. To illustrate clinical applicability, a xeno-free hES-MP cell line was also derived. None of the markers characteristic
for undifferentiated hES cells were detected in the hES-MP cells. Instead, these cells were highly similar to mesenchymal
stem cells with regard to morphology and expression of markers. The safety of hES-MP cells following transplantation was
studied in severely combined immunodeficient (SCID) mice. The implanted hES-MP cells gave rise to homogeneous,
well-differentiated tissues exclusively of mesenchymal origin and no teratoma formation was observed. These cells further
have the potential to differentiate toward the osteogenic, adipogenic, and chondrogenic lineages in vitro. The possibility of
easily and reproducibly generating highly expandable hES-MP cell lines from well-characterized hES cell lines with
differentiation potential into several mesodermal tissues entails an enormous potential for the field of regenerative medicine.
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provide a unique source of functional human cells for future
cell therapy and tissue engineering. Since hES cell lines can
be expanded in vitro without an apparent limit in the
number of cell doublings and also have the potential to
differentiate into derivatives of all three embryonic germ
layers (pluripotency), they are a potentially valuable source
of cells where autologous cells cannot be used. Some
progress has been made in directing hES cell differentiation
toward specific cell types such as neural cells (Carpenter.
40 C. Karlsson et al.et al., 2001), hepatocyte-like cells (Lavon et al., 2004),
pancreatic cells (D'Amour et al., 2006), cardiomyocytes
(Kehat et al., 2003), or connective tissue cells (Sottile et al.,
2003). However, the direct derivation of pure populations of
functionally differentiated cells from hES cells still poses a
challenge and there is a significant risk that the transplanta-
tion of undifferentiated hES cells may lead to tumor
formation in the recipients. Progenitor cells are immature
cells in an intermediate stage of development, i.e., between
stem cells and fully mature cells. Like stem cells, progenitor
cells have a capacity for self-renewal and differentiation,
but these properties are more limited, i.e., progenitor cells
have a more finite lifespan and give rise to a more lineage-
restricted progeny (multipotency). From a safety aspect, the
application of progenitor cells instead of undifferentiated
hES cells for therapeutic purposes is favorable since the
differentiation pathway is already partly determined and the
risk of tumor formation should therefore be reduced. From a
technical point of view, progenitor cultures are expected to
be more stable and easier to scale up in vitro than
undifferentiated hES cells, which would provide an advan-
tage for bulk production of cells for therapy.
Of great interest in this context is the functionality and
phenotype of the progenitors during embryogenesis and
early human development. In human, the exact cellular
interactions during embryogenesis and the properties
required for normal maturation into functional cells and
tissues during the early stages are sparsely explored. Instead
parallels are often drawn to other species which can be more
easily examined (Kerszberg and Wolpert, 2000). During the
allocation of cells to the three germ layers, the embryonic
mesoderm develops from the primitive streak by an
epithelial–mesenchymal transition process (Ullmann et al.,
2007). This development starts around Days 13–15 when cells
migrate through the primitive streak to form the mesodermal
layer. The extraembryonic mesoderm might have a dual
origin developing through extraembryonic endoderm and the
yolk sac or as a branching from the actual embryonic
mesoderm. Segmentation of the paraxial mesoderm into
somites continues to separate the lateral plate mesoderm
into somatic and splanchnic mesoderm. The further devel-
opment toward cartilage and even more complex organized
structures like joints is thought to start with interrupted
condensed mesenchymal structures but the exact mechan-
isms for this development remain to be fully explored
(Pacifici et al., 2006). Theoretically, mesenchymal progeni-
tors derived from hES cells should have the developmental
potential to recapitulate these processes and research to
develop germ-layer-specific progenitor cells from hES cells
has been ongoing. With respect to the mesoderm, progenitor
cell lines have been derived from hES cells by transfection
with human telomerase reverse transcriptase (Xu et al.,
2004), by coculture with mouse OP9 cells (Barberi et al.,
2005), by fluorescence-activated cell sorting (Lian et al.,
2006) or by manual selection of cell populations (Stojkovic
et al., 2005; Olivier et al., 2006).
We have developed optimized protocols allowing the
simple and reproducible derivation of mesenchymal progeni-
tor (hES-MP) cell lines from undifferentiated hES cells. The
protocols do not require cell transfection, coculture, cell
sorting, or subjective manual selection and give rise to highly
similar hES-MP cell lines with a mesenchymal morphology,extended in vitro expandability and the potential to give rise
to derivates of the mesoderm. We further demonstrate the
universal applicability and reproducibility of the method by
deriving multiple hES-MP cell lines from 10 different parental
hES cell lines and show for the first time that derivation and
culture of hES-MP cells could be performed under xeno-free
conditions from a xeno-free parental hES cell line. With
respect to future clinical suitability we show that hES-MP
cells consistently survive transplantation and develop into
several connective tissues in vivo, without generating
teratoma.
Results
Derivation and culture of hES-MP cell lines
The robust method developed to derive hES-MP cell lines
from undifferentiated hES cell lines is based on the
application of a selective pressure which favors fast growing
cells with an ability to attach and proliferate in feeder-free
monolayer culture. These conditions provide a growth
advantage for hES-MP cells while slow-growing differen-
tiated cell types as well as undifferentiated hES cells were
eliminated.
Consecutive enzymatic passaging as single cell suspen-
sions under the described conditions reproducibly led to the
derivation of morphologically homogeneous hES-MP cell
lines from high-density cultures of pluripotent undifferen-
tiated hES cells within 2–3 passages (Fig. 1). The high-
density plated hES cells initially gave rise to a mixed
population of various differentiating cell types (Fig. 1a).
Each consecutive passage decreased the amount of con-
taminating cell types and the cultures became increasingly
homogeneous (Figs. 1b–d). The hES-MP cells phenotypically
resemble mesenchymal cells with typical fibroblast like
morphology, i.e., elongated spindle-shaped cell morphology
with branching pseudopodi (Fig. 1e). The morphologies of
both hES-MP cells and mesenchymal stem cells (MSCs) are
significantly different from those of undifferentiated hES
cells (Fig. 1f).
Xeno-free derivation and expansion of hES-MP cells
To derive hES-MP cells from a xeno-free hES cell line without
contaminating the cell cultures with animal protein, all
animal-derived components were replaced with human-
derived or recombinant components. Human serum was
used in the culture medium instead of FBS and human
recombinant gelatin was used instead of porcine gelatin to
coat culture dishes. Using these modified protocols, a xeno-
free hES-MP cell line was derived from the xeno-free hES cell
line SA611 (Ellerström et al., 2006). On removal from the
supporting human foreskin fibroblast (hFF) feeder layer and
transfer to high-density culture, the xeno-free hES cells
initially showed an outgrowth pattern with less distinct
three-dimensional structures. But already after two passages
the arising xeno-free hES-MP cells were morphologically
indistinguishable from the previously established non-xeno-
free lines (Figs. 1g, h).
The protocols for the derivation of hES-MP cell lines
showed excellent reproducibility and robustness. Multiple
Figure 1 Morphology of hES-MP cells during derivation from hES cells. After subsequent passage, these fast growing hES-MP cells
quickly become the dominant cell type in the culture resulting in a homogeneous population of cells (a–d). (a) p0 high-density culture
(scale bar 100 μm), (b) p2 (scale bar 100 μm), (c) p3 (scale bar 250 μm), (d) p7 (scale bars 250 μm). Human MSCs cultured in monolayer,
p3, scale bar 200 μm (e). Morphology of undifferentiated hES cells (f). Xeno-free hES-MP cells were established from hESC line SA611
(g, h). (g) p2, (h) p4 (scale bars 200 μm).
41Human embryonic stem cell-derived mesenchymal progenitors—Potential in regenerative medicinehES-MP cell lines were successfully derived and cultured
from 10 different hES cell lines (number of establishments
per cell line are shown in brackets), SA001(3), SA002 (3),
SA002.5 (10), AS034 (2), AS034.1.1 (1), SA121 (6), SA167 (7),
SA348 (1), SA461 (1), and SA611(1).To exclude the possibility that the observed fast growing
cell populations may actually be mouse embryonic fibro-
blasts that had not been sufficiently growth inactivated and
had been transferred from the feeder layer by accident we
performed immunostainings with an antibody specific for
Figure 2 Monolayer culture of hES-MP cells stained with
α-human nuclei antibody demonstrating the cells to be of human
origin. The hES-MP cell line SA002.5 (p5) staining positive for
α-human nuclei antibody (a), DAPI staining (b) (scale bars 50 μm).
42 C. Karlsson et al.human nuclei on hES-MP cell cultures. These stainings clearly
confirmed that all cells were human (Fig. 2).
Characterization of hES-MPs cell lines
None of the markers typically found in undifferentiated hES
cells (Oct-4, Nanog, TRA 1-60, TRA 1-81, SSEA-3, SSEA-4) nor
the early differentiation marker SSEA-1 could be detected in
hES-MP cell cultures in the proliferative state (Fig. 3). Both
endodermal markers (HNF3β and AFP) and neuroectodermal
markers (nestin, GFAP, and β-III-tubulin) were undetectable.
The epithelial markers E-cadherin and Pan-cytokeratin were
also negative. However, the early mesodermal markers
desmin and vimentin were clearly expressed in almost all
cells, while α-smooth muscle actin (α-SMA) was expressed in
individual cells in the proliferative state (Figs. 3a, c, e). A
high percentage (≥75%) of all four hES-MP cell lines analyzed
(SA002, SA002.5, SA167, and SA461) as well as human MSCs
were further positive for several markers characteristic for
mesenchymal stem cells (CD105, CD166, CD10, CD13) and
negative for the neuroprogenitor marker CD133 and the
hematopoietic stem cell marker CD117 compared to undif-
ferentiated hES cells analyzed by flow cytometry (Fig. 4).
To allow bulk production, the hES-MP cells were cultured
in flasks and passaged every 7 days at a split ratio of 1:10. At
high densities when the cultures were ready for passage the
hES-MP cells showed a more elongated morphology (Fig. 1d).Figure 3 Immunocytochemical markers, (a and b) desmin, (c and
cell line SA001 in the proliferative state (a, c, e) and after assisted mo
of immunohistochemical characterization of hES-MP cells in proliferUsing this 7 day passage interval, the hES-MP cell lines could
be expanded massively for 16–20 passages before a decrease
in proliferative capacity was detected.
Differentiation and growth arrest could be induced in
monolayer cultures by switching the hES-MP cell cultures to a
serum-free hES-MP medium without hrbFGF, thus withdraw-
ing mitogenic growth factors. Under those conditions pro-
liferation of the hES-MP cells nearly halted within 14 days
while the cell morphology became significantly more spread
out and flattened. Cytoskeletal elements became more
pronounced in phase contrast microscopy. The cells are still
negative for ectodermal, endodermal, and epithelial markers
while the mesodermal markers desmin and vimentin were
highly expressed in almost all cells. Interestingly, an abundant
expression of α-SMA was also detected (Figs. 3b, d, f).
To evaluate whether hES-MP cells could be steered back to
a less differentiated state by the signals which maintain
pluripotency in hES cells, proliferating hES-MP cells were
transferred to the traditional mouse embryonic fibroblast
(MEF) feeder-layer-supported growth conditions for undiffer-
entiated hES cells. Even under these conditions no evidence
of de-differentiation could be found. The hES-MP cells rapidly
formed a confluent monolayer while maintaining a mesench-
ymal morphology. No cells with undifferentiated hES cell
morphology could be detected and immunocytochemical
analysis, with the undifferentiated hES cell markers Oct-4,
SSEA-1, and TRA-1-60, was negative (data not shown).
Transplantation of hES-MP cells
To examine the differentiation potential of the hES-MP cells
in vivo and to assess the risk of tumor formation after
transplantation, clusters of hES-MP cells were injected under
the kidney capsule of SCID mice. After 8 weeks the mice were
sacrificed and the kidneys were surgically removed. In each
case the injected hES-MP cells had given rise to 1- to 2-mm
oval tissue structures with sharp boundaries under the kidney
capsule. The tissue formed by the hES-MP cells was
macroscopically clearly visible, but very small compared to
the massive teratoma which develops after transplantation
of smaller numbers of undifferentiated hES cells (Heins et
al., 2004, 2005) and reach an average size of 1–2 cm within 8
weeks. Obviously, growth of hES-MP cells after transplanta-
tion is very limited. Histological evaluation of the tissue
which had developed from the injected cells showed various
tissues of mesenchymal origin (Figs. 5a–e). The presence of
cartilage was confirmed by Alcian blue van Gieson and
Safranin-O staining (Figs. 5b, c).
The injected hES-MP cells had remained within a small,
well-limited area at the injection site, and the developed
tissue showed clearly defined boundaries toward the tissue
of the mouse renal cortex. No sign of invasive growth into the
surrounding tissue could be detected in serial cross sections.
Even at the microscopical level no indication of teratoma
formation from the transplanted hES-MP cells could be
observed. All parental undifferentiated hES cell lines on the
contrary formed teratoma (Heins et al., 2004, 2005;d) vimentin, (e and f) α-SMA, shown in hES-MP cultures from hES
nolayer differentiation (b, d, f) (scale bars 100 μm). (g) Summary
ative and differentiated state.
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Figure 4 Representative flow cytometric analysis of hES-MP cells and undifferentiated hES cells from the same cell line (SA002.5) as
well as human MSCs for CD105 (a), CD166 (b), CD13 (c), CD10 (d), CD117 (e), and CD133 (f). Black histograms; hES-MP cells, gray
histograms; MSCs white histograms; undifferentiated hES cells, line; fluorescence intensity considered as positive signal obtained from
isotype controls.
44 C. Karlsson et al.Ellerström et al., 2006) which comprised a mixture of tissues
from all germ layers and showed invasive growth into the
renal cortex (Fig. 5f).
The human origin of the developed tissues was confirmed
bywhole genomehumanDNA–FISHon the cross sections of the
tissue. Positive staining with the human probe was detected
only in areas of tissue formation from the transplanted hES-MP
cells, verifying that the hES-MP cells had human origin.
Chondrogenic differentiation
Differentiation of the hES-MP cell lines in Hyaff-11 scaffolds
demonstrated cells evenly dispersed throughout the scaffold
(Fig. 5a). Microscopical evaluation revealed that the cells
produced large amounts ofmatrix. Alcian blue van Gieson and
Safranin-O stainings demonstrated the presence of sulfated
proteoglycans characteristic for a cartilaginous matrix
(Fig. 5a). Accumulation of collagen type II was also detected
(Figs. 5b, c). Differentiation into the chondrogenic lineage
for both hES-MP cells and MSCs was also performed using the
high-density pellet mass culture system. Cartilagematrix was
produced by the hES-MP cells also in this chondrogenic assay,
although less accumulation of cartilage matrix was detected
compared to that of the MSC pellets (Figs. 5d, e).Osteogenic differentiation
The osteogenic potential of the hES-MP cells as well as MSCs
was demonstrated in a 2D culture system in which miner-
alization was studied using von Kossa staining (Figs. 6f, g).
Adipogenic differentiation
After 25 days of incubation in adipogenic medium, the hES-
MP cells changed morphology from a fibroblast-like to a more
spherical shape. Adipogenic differentiation further resulted
in lipid droplet formation characteristic for adipocytes as
well as oil-red O-positive cells, although a larger population
of MSCs differentiated toward the adipogenic lineage
compared to that of the hES-MP cells (Figs. 6h, i).
Discussion and conclusions
The aim of this study was to bring forth robust and
reproducible protocols for the derivation of mesenchymal
progenitors from hES cells primarily for the future use in
tissue engineering and cell therapies. Nevertheless, easily
derived and cultured cell lines with high human relevance
Figure 5 In vivo transplantation of hES-MP cells under the renal capsule in SCID mice resulted exclusively in differentiation toward
mesenchymal tissues. Only small, well-differentiated tissues were formed compared to mixed teratomas obtained from
undifferentiated hES cells. (a) Cartilage, (b) confirmation of cartilage by Alcian blue van Giesson staining, and (c) Safranin O
staining, (d, e) mixed mesodermal structures, i.e., cartilage, and (f) teratoma formed from undifferentiated hES cells with the three
germ layers represented (scale bars 100 μm).
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testing, especially in screening applications.
The derivation of mesenchymal stem cell-like or fibro-
blast-like cells from hES cells using different protocols has
been described earlier. The reported methods, for example,
use transfection with human telomerase reverse transcrip-
tase (Xu et al., 2004), coculture with mouse OP9 cells
(Barberi et al., 2005), selection of cell populations by
fluorescence-activated cell sorting (Lian et al., 2006), or
by manual selection of cell populations (Stojkovic et al.,
2005; Olivier et al., 2006). Neither of the protocols yet
addresses the important aspects of xeno-free derivation,
robustness, and safety for the use in tissue engineering and
cell therapies. We here report the development of simplified
protocols which do not require any of the above steps and
allow quick and reproducible establishment of stable
progenitor lines with the potential to give rise to derivates
of the embryonic mesenchyme. The derivation method isbased on highly selective culture conditions which result in
morphologically homogeneous hES-MP populations within 2–
3 passages. The high reproducibility of the method is
demonstrated by the successful derivation of multiple hES-
MP cell lines from a variety of parental hES cell lines.
An additional advantage of the present approach is that
the protocols can be modified to allow the derivation and
cultivation of hES-MP cells in the absence of animal-derived
components. Other methods described so far involve, as
described above, viral infection of exogenous DNA, coculture
with animal-cells, or cell sorting using animal-derived
monoclonal antibodies which makes the clinical suitability
of these cell lines questionable. We were able to humanize
our protocols to derive and expand a xeno-free hES-MP cell
line from a xeno-free parental hES cell line (Ellerström et al.,
2006) utilizing proven components and conditions which have
been applied for the GMP-grade production of autologous
chondrocytes for clinical use (Brittberg et al., 2003).
Figure 6 In vitro differentiation of the hES-MP cells toward mesodermal lineages. Chondrogenic differentiation in Hyaff-11 scaffolds
analyzed by Alcian blue van Gieson staining (a) and immunohistochemistry for collagen type II (b). Negative control for collagen type II
staining (c). Chondrogenic differentiation in high-density pellet mass cultures stained with Alcian blue van Gieson staining (c, d),
osteogenic differentiation analyzed by von Kossa staining (e, f), and adipogenic differentiation analyzed by oil-red O staining (g, h).
hES-MP cells (a–c, e, g, i) and human MSCs, (d, f, h).
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an excellent proliferative capacity. They can be grown on
uncoated tissue culture plastic in a variety of formats
and do not require feeder cells or conditioned medium.
These characteristics make the cell lines suitable for large-
scale in vitro expansion. We demonstrate for the first
time that the commonly used FBS (Barberi et al., 2005;
Olivier et al., 2006) can be replaced by human serum to
provide an animal-protein free environment for hES-MP cell
expansion.
Mitogenic culture conditions can be used to maintain the
hES-MP in a proliferative progenitor state over an extended
period of time. Differentiation appears to occur only
sporadically in individual cells which take on a more
differentiated phenotype accompanied by the expression
of alpha smooth muscle actin (α-SMA). Withdrawal of growth
factors under serum-free conditions can be used to assist
differentiation of the hES-MP cells in monolayer cultures.
The hES-MP cultures enter growth arrest and take on a moremature phenotype indicated by dramatically increased α-
SMA expression and a clear change in cell morphology while
the marker profile remains exclusively mesodermal.
From a clinical point of view, cell therapy critically
depends on a fine balance concerning the degree of
differentiation of the cells to be transplanted. Grafted
cells must be able to survive and form tissue, whereas
tumorogenicity must be avoided under any circumstances.
Bone-marrow-derived mesenchymal stem cells, for example,
tend to show poor survival and integration after implantation
to SCID mice (Thalmeier et al., 2001; Xia et al., 2004) while
undifferentiated hES cells consistently give rise to tumors
(Thomson et al., 1998; Heins et al., 2004). No teratoma
formation could be observed after transplantation of hES-MP
cells into SCID mice. The small, well-defined connective
tissues that developed from the transplanted hES-MP cells
were distinctly different from the large, mixed germ-layer
tumors which arise after transplantation of undifferentiated
hES cells. These results are thus in accordance with the
47Human embryonic stem cell-derived mesenchymal progenitors—Potential in regenerative medicinehomogeneous expression pattern of mesodermal markers
exclusively on the hES-MP cells compared to the undiffer-
entiated hES cells. These results further demonstrate the
phenotypical similarity between hES-MP cells and MSCs. The
stability of the hES-MP cells was further demonstrated by
culturing the cells in an environment favoring growth of
undifferentiated hES cells, showing that the hES-MP cells had
lost the potential for complete de-differentiation and were
unable to regain pluripotency. The mesodermal phenotype
and potential therapeutic use of these cells were also
demonstrated by their potential to differentiate into the
osteogenic, chondrogenic, and adipogenic lineages.
Mesenchymal stem cells can be isolated from the bone
marrow and from other connective tissues, but availability
depends on suitable donors and the proliferative properties
(Hwang et al., 2006) and the long-term expandability of
these cells in vitro is rather poor (Otto and Rao, 2004;
Barberi et al., 2005). The sophisticated infrastructure which
is currently being built up for hES cell line banking,
production, and distribution would allow the derivation of
hES-MP cell lines from well-characterized hES cell lines with
a wide variety of genetic backgrounds and specific proper-
ties. From any parental hES cell line, a virtually unlimited
amount of genetically identical hES-MP cells could be
produced for therapeutic purposes. Until possible immune
compatibility problems between hES cell-derived cells and
recipients are resolved, cell-based therapy may not be
considered practical (Lian et al., 2006). In the meantime,
stable, easily handled progenitor lines nevertheless have a
great potential as a unique source of highly consistent human
cells for research, toxicity testing, and drug discovery
(McNeish, 2004; Elisseff, 2004) as well as for the xeno-free
in vitro production of human biologicals, ECM components,
or human mesenchymal stem cell-derived cytokines (Caplan
and Dennis, 2006).
Materials and methods
hES cell lines used
Ten different hES cell lines were used for the derivation of
hES-MP cell lines. All hES cell lines had been established and
characterized at Cellartis AB, Gothenburg, Sweden. The
establishment, clonal derivation, characterization, and
subsequent culture of hES cell lines SA001, SA002, SA002.5,
AS034, AS034.1.1, SA121, SA167, SA348, and SA461 had been
carried out as described previously (Heins et al., 2004, 2005).
The xeno-free hES cell line SA611 was established,
expanded, and characterized as recently described (Eller-
ström et al., 2006).
Derivation of hES-MP cell lines and subsequent
expansion
Undifferentiated hES cells were removed from the support-
ing feeder layer, enzymatically dissociated with TrypLE
Select (Gibco/Invitrogen, Paisley, UK), and plated onto 0.1%
porcine gelatin-coated cell culture dishes (BD Falcon/BD
Biosciences, Bedford, MA, USA) as high-density cultures at
1.5×105 cells/cm2 in hES-MP medium consisting of DMEM-HG
(with glutamax, without pyruvate) supplemented with 10%fetal bovine serum (FBS) and 10 ng/ml human recombinant
basic fibroblast growth factor (hrbFGF) (all from Gibco/
Invitrogen). The plated hES cells were left to differentiate
for 7 days in a humidified atmosphere at 37 °C and 5% CO2
resulting in an outgrowth of heterogeneous cell types. To
initiate the derivation of hES-MP cells, the hES cells were
then passaged enzymatically (passage 1, p1) as a single cell
suspension using TrypLE Select to gelatin-coated culture
dishes. In this and in all following passages or transfer steps,
no selection was performed manually or otherwise; i.e., all
cells were transferred. This procedure was repeated every 7
days until the cell population became homogeneous for hES-
MP morphology (at p2–p3). Following the initial derivation
steps, the hES-MP cells were cultured in uncoated tissue
culture flasks (BD Falcon, BD Biosciences) in a humidified
atmosphere at 37 °C and 5% CO2 and enzymatically
passaged with TrypLE Select every 7 days at a split ratio
of 1:10.
Xeno-free modifications for derivation and
expansion of hES-MP cell lines
In order to derive a xeno-free hES-MP cell line, FBS was
replaced with human serum (HS) in the hES-MP medium.
Human serum was prepared and tested as described earlier
(Ellerström et al., 2006). Human recombinant gelatin
(Fibrogen, San Francisco, CA, USA) was used to coat culture
dishes instead of porcine gelatin. Alternatively, noncoated
tissue culture flasks were used for expansion with similar
efficiency.
Isolation of human mesenchymal stem cells
Bone marrow was obtained from four patients undergoing
spinal fusion (mean age 45 years, range 32–54). Mesenchy-
mal stem cells were isolated from the bone marrow by
gradient centrifugation using CPT tubes prefilled with Ficoll
(Pharmacia, Uppsala, Sweden) according to manufacturer's
instructions. The cells were then expanded in DMEM-LG
(Invitrogen), supplemented with the same additives as
described above for the expansion of hES-MP cells.
Flow cytometry analysis
The purity of the population of MSCs was evaluated using
flow cytometry. MSCs in passage 3 were harvested at 80%
confluence using 0.05% trypsin–0.53 mM EDTA (Gibco, Grand
Island, NY, USA). These cells were then stained with
antibodies against hematopoietic stem cells and endothelial
cells (CD34), white blood cells (CD45), and MSCs (CD105,
D166) (Ancell, Bayport, MN).
The phenotype of the hES-MP SA002, SA002.5, SA167, and
SA461 cell lines and undifferentiated hES cell parental cell
lines as well as human MSCs were studied by flow cytometry
analysis for a panel of different markers (CD105, CD166 (both
antibodies from Ancell, Bayport, MN), CD10, CD13, CD117,
and CD133 (all four antibodies from BD Biosciences, Heidel-
berg, Germany)). Colonies of undifferentiated hES cells
cultured on a supporting feeder layer were dissected out and
treated with 0.05% trypsin–0.53 mM EDTA to obtain a single
cell suspension. The hES-MP cells lines and human MSCs were
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fluence and were then harvested using 0.05% trypsin–
0.53 mM EDTA.
At least 10 000 events were acquired for each sample
using the FACS Aria flow cytometer and the FACSDiVa
software (Becton Dickinson). The 488 nm argon ion laser
was used to excite samples, with emission being measured
using appropriate bandpass filters. The cells were acquired
and gated by forward (FSC) and side scatter (SSC) to exclude
debris and cell aggregates. Dead cells were excluded by
gating on FSC and SSC. To calculate the percentages of cells
staining positive for each marker, a maximum of 2% positive
cells stained with isotype control antibody was allowed.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde solution (Histolab
Products AB, Västra Frölunda, Sweden) for 10 min at room
temperature, permeabilized with 0.5% Triton X-100 (Sigma-
Aldrich, St. Louis, MO, USA). Nonspecific binding of the
antibodies was prevented by incubating the sections in 10%
FBS in PBS (Gibco/Invitrogen) for 30 min before incubation
with primary antibodies (Table 1a, supplementary data) for
20 h at 4 °C, followed by a 1 h incubation with secondary
antibodies (Table 1c, supplementary data) at 4 °C. Negative
controls were included in which the primary antibodies were
omitted. Primary and secondary antibodies were purchased
according to Table 1 (supplementary data). DAPI (4′,6-
diamidino-2-phenylindole) staining (Sigma-Aldrich), interca-
lating with the DNA was used to visualize cell nuclei in all
antibody stainings.
Differentiation and tissue formation in vitro
In order to induce spontaneous differentiation in vitro of
hES-MP cells in monolayer culture, hrbFGF was withdrawn
from the hES-MP cell culture medium and FBS was replaced
by SR (serum replacement, Gibco/Invitrogen). The cells were
then left to differentiate for 14 days in a humidified
atmosphere at 37 °C and 5% CO2. Culture medium was
renewed every 2–3 days. Phenotypical analysis was per-
formed using immunohistochemistry as described above.
Osteogenic differentiation
Triplicate cultures of both hES-MP cells and human MSCs were
seeded at a density of 4000 cells/cm2. The cells were
cultured in DMEM-LG supplemented with 10% FBS, 80 μm
ascorbic, acid-2-phosphate (Wako Chemicals, USA), 1 μM
dexamethasone (Sigma-Aldrich), and 20 mM β-glycerol
phosphate (Sigma-Aldrich).
After 5 weeks of culture, the cells were analyzed for
mineralization with microscopic inspection and von Kossa
staining. For von Kossa staining, the cells were first washed
twice in PBS and fixed using Histofix for 30 min and again
rinsed twice with water. The water was removed and 2%
silver nitrate (Sigma-Aldrich) solution was added. The plate
was kept in the dark for 10 min and then rinsed three times
with water before being exposed to bright light for 15 min.
The cells were rinsed twice and then quickly rehydrated in
100% EtOH.Chondrogenic differentiation
The chondrogenic potential of the hES-MP cells and human
MSCs was investigated using the high-density pellet mass
culture system. Briefly, 4×105 cells were placed into a
conical polypropylene tube. The cells were incubated in
0.5 ml of defined medium, consisting of DMEM-HG supple-
mented with 5.0 μg/ml linoleic acid (Sigma-Aldrich), 1X
insulin, transferring, and selenium (ITS-G concentrate, Life
Technologies, Paysley, UK), 1.0 mg/ml human serum albumin
(Equitech-Bio, Kerrville, TX, USA), 10–7 M dexamethasone,
14 μg/ml ascorbate acid (Sigma-Aldrich) 10% FBS, 20 ng/ml
TGF-β1 (R&D Systems, Abingdon, UK), and 1% penicillin-
streptomycin (PEST [PAA Laboratories]). The cells were
centrifuged at 500g for 5 min and the medium was changed
twice a week.
In order to study a possible clinical application of the hES-
MP cells, culture of the cells in Hyaff-11 (Fidia Advanced
Biopolymers, Abano Terme, Italy) scaffolds were performed.
Cells from both hES-MP cell lines SA002.5 and SA167 were
seeded in Hyaff-11 scaffolds prcoated with human serum at a
cell density of 4×106 cells/cm2. The cells were cultured in
the medium described above for 6 weeks.
After 6 weeks in Hyaff-11 cultures or 3 weeks in pellet
mass cultures, the specimens were fixed in Histofix,
dehydrated with EtOH, and embedded in paraffin. Five-
micrometer sections were cut and placed onto silane-coated
glass slides. The sections were deparaffinized and stained
with Safranin-O and Alcian blue van Gieson (HistoCenter) and
were then observed with a light microscope (Nikon, Japan).
The sections from the Hyaff-11 cultures were also used to
immunohistochemically detect collagen type II. The sections
were deparaffinized, dehydrated, digested with hyaluroni-
dase, 8000 units/ml (Sigma-Aldrich) in PBS for 1 h at 37 °C,
and blocked with 3% BSA (Sigma-Aldrich). Sections were
labeled with monoclonal antibodies raised against collagen
type II (anti-collagen type II (ICN Biomedicals, Aurora, OH,
USA)) diluted 1:150 in PBS containing 3% BSA. Primary
antibodies were visualized using a HRP-conjugated second-
ary antibody (HRP-conjugated goat-anti-mouse) (Jackson
Laboratory, Maine, ME, USA), diluted 1:150. All incubations
were performed at room temperature in a humidified
chamber for 1 h. Primary antibodies were visualized using
the TSA-Direct Cy3 kit (Perkin Elmer, Boston, MA, USA)
according to the manufacturer's instructions. After washing
in PBS, nuclei were stained with DAPI (Sigma-Aldrich) and the
slides were mounted in antifading medium. The sections
were then analyzed with a Nikon fluorescence microscope
and digital pictures were taken with the ACT-1 software.
Positive controls were sections from goat hyaline cartilage
obtained from the knee and negative controls were sections
incubated with only secondary antibody.
Adipogenic differentiation
To induce adipogenesis, hES-MP cells derived from SA002.5
and SA167 as well as human MSCs were plated onto tissue
culture treated 24-well plates at a seeding density of 104
cells/cm2. Triplicate cultures were incubated with DMEM-LG,
20% FBS, 5 μg/ml insulin, 10-6 M dexamethasone, 0.5 mM
isobutylmethylxanthin, and 60 μm indomethacin, all from
Sigma-Aldrich, with medium changes twice a week.
49Human embryonic stem cell-derived mesenchymal progenitors—Potential in regenerative medicineAfter 25 days of culture, the cells were analyzed for lipid
content with microscopic inspection and oil-red O staining
(Merck, Darmstadt, Germany). For oil-red O staining, the cells
were washed in PBS and fixed in Histofix for 10 min. The cells
were then stained with oil-red O solution (in 60% isopropanol)
for 1 h followed by repeated washings with water.
Dedifferentiation of hES-MP cells
hES-MP cells were enzymatically removed from the culture
dishes using TrypLE Select and seeded onto a growth-
inactivated MEF feeder cell layer in VitroHES supplemented
with 4 ng/ml hrbFGF. The cocultures were incubated for 10
days in a humidified atmosphere at 37 °C and 5% CO2. Culture
medium was renewed every 2–3 days.
In vivo differentiation
For assessment of the safety aspects concerning transplan-
tation of the hES-MP cells for use in therapies and tissue
engineering as well as to examine the in vivo differentiation
potential of the hES-MP cells, four of the different hES-MP
cell lines were examined in vivo (SA001, SA002.5, AS034,
and SA121). The transplantations were done repeatedly with
the hES-MP cell lines between passage 5–15 and repeated in
2–8 mice for every cell line. Approximately 200 000 hES-MP
cells were mechanically scraped loose from the culture
plate and surgically placed under the kidney capsule of
5-week-old SCID (severe combined immunodeficiency) mice
(CB-17/lcrCrl-Scid, Sulzfeld, Charles River Laboratories,
Germany). The mice were sacrificed after 8 weeks and the
kidneys were surgically removed. All animal studies had
been reviewed and approved by the Institutional Animal
Care and Use Committee at Göteborg University in accor-
dance with the policy regarding the use and care of
laboratory animals. The tissue samples were then fixed in
4% paraformaldehyde solution (HistoLab Products AB) for
24 h and embedded in paraffin. The tissue samples were
sectioned at a thickness of 6–9 μm and were evaluated
histologically following hematoxylin-eosin and Safranin O
staining (HistoCenter).
Confirmation of human origin
To confirm the human origin of the tissues developed under
the fibrous capsule of the mouse kidneys, a whole genome
human DNA–FISH probe (Spectrum Red-labeled total human
genomic DNA, Vysis Inc, Downers Grove, IL, USA) was used to
exclusively label human cell nuclei as described previously
(Gertow et al., 2004).
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